TD Private Client Wealth LLC Increases Holdings in Sanofi (NASDAQ:SNY)

TD Private Client Wealth LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 16.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 108,510 shares of the company's stock after buying an additional 15,477 shares during the period. TD Private Client Wealth LLC's holdings in Sanofi were worth $6,018,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after acquiring an additional 408,752 shares during the last quarter. Bank of America Corp DE boosted its position in Sanofi by 3.8% during the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after purchasing an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Boston Partners lifted its stake in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after buying an additional 369,530 shares during the period. Institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SNY shares. Guggenheim reissued a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday. BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research report on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $61.50.

Sanofi Price Performance

NASDAQ SNY traded up $0.02 during trading on Monday, reaching $48.32. The company's stock had a trading volume of 2,305,572 shares, compared to its average volume of 2,338,380. The firm has a fifty day moving average of $50.61 and a 200 day moving average of $52.12. Sanofi has a one year low of $45.80 and a one year high of $60.12. The stock has a market capitalization of $118.50 billion, a PE ratio of 17.26, a P/E/G ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.78 earnings per share. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is currently 56.79%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.